Our study highlights H3K36me2 as a potential biomarker for patient stratification and positions NSD2 as a promising therapeutic target across HNSCC subtypes, modulating both common and subtype-specific oncogenic pathways. The gene discussed is NSD2; the disease is head and neck squamous cell carcinoma.